NEW YORK (GenomeWeb) – Christiana Care announced today that its Gene Editing Institute of the Helen F. Graham Cancer Center & Research Institute has licensed gene-editing technology to Israeli personalized medicine firm NovellusDx as part of an ongoing cancer research collaboration.
In January, the Philadelphia-based Gene Editing Institute secured a $900,000 grant from the Binational Industrial Research and Development Foundation to work with NovellusDx to recreate genetic mutations involved in cancer in order to identify and design personalized therapies. At the time, the partners were still negotiating a license to the institute's gene-editing technology.
Now that license has been finalized, NovellusDx will have access to the technology in exchange for 10 years of royalties. Additional terms were not disclosed.
"The technology we are commercializing from the Gene Editing Institute will allow us to go from next-generation sequencing data to real genes with all of the specific patient's mutations faster and with more reliability, allowing us to scale-up and meet our demand while reducing the turnaround time," NovellusDx COO Michael Vidne said in a statement.